Oruka Therapeutics, Inc. Proceeds from Sale and Maturity of Debt Securities, Available-for-sale
Oruka Therapeutics, Inc. (ORKA) reported Proceeds from Sale and Maturity of Debt Securities, Available-for-sale of $3.05 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-02-18.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities · last filed 2020-02-18
- Oruka Therapeutics, Inc. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- Oruka Therapeutics, Inc. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- Oruka Therapeutics, Inc. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- Oruka Therapeutics, Inc. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2018-03-31 was $3.05M, a 32.97% decline year-over-year.
- Oruka Therapeutics, Inc. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2018 was $3.05M, a 83.42% decline from fiscal 2017.
- Oruka Therapeutics, Inc. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2017 was $18.40M, a 348.56% increase from fiscal 2016.
- Oruka Therapeutics, Inc. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2016 was $4.10M.
| Period end | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 3 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 6 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 9 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-18 | $0.00 derived: sum of 2 quarters · filed 2020-02-18 | $0.00 derived: sum of 3 quarters · filed 2020-02-18 | $3.05M 10-K · filed 2020-02-18 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $3.05M 10-Q · filed 2019-11-06 | $7.80M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $3.05M 10-Q · filed 2019-08-01 | $7.80M derived: sum of 3 quarters · filed 2019-08-01 | $10.30M derived: sum of 4 quarters · filed 2019-08-01 |
| 2018-03-31 | $3.05M 10-Q · filed 2019-05-08 | $7.80M derived: sum of 2 quarters · filed 2019-05-08 | $10.30M derived: sum of 3 quarters · filed 2019-05-08 | $16.90M derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | $4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $7.25M derived: sum of 2 quarters · filed 2019-02-27 | $13.85M derived: sum of 3 quarters · filed 2019-02-27 | $18.40M 10-K · filed 2019-02-27 |
| 2017-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $9.10M derived: sum of 2 quarters · filed 2018-11-14 | $13.65M 10-Q · filed 2018-11-14 | $16.80M derived: sum of 4 quarters · filed 2018-11-14 |
| 2017-06-30 | $6.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $11.15M 10-Q · filed 2018-08-09 | $14.30M derived: sum of 3 quarters · filed 2018-08-09 | $14.80M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $4.55M 10-Q · filed 2018-05-08 | $7.70M derived: sum of 2 quarters · filed 2018-05-08 | $8.20M derived: sum of 3 quarters · filed 2018-05-08 | |
| 2016-12-31 | $3.15M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-22 | $3.65M derived: sum of 2 quarters · filed 2018-03-22 | $4.10M 10-K · filed 2018-03-22 | |
| 2016-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $950.00K 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $450.00K 10-Q · filed 2017-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |